Would you consider offering neoadjuvant concurrent chemoradiation to a young (<50) patient with adenocarcinoma of the GE junction with a site of solitary metastasis (bone)?
Provided the patient can have the solitary met treated definitively with SBRT and is otherwise a good surgical candidate